Drug General Information (ID: DDI7AT98HR)
Drug Name			Ziprasidone		Drug Info		Bicalutamide		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antipsychotic Agents				Antineoplastics
Structure

Mechanism of Ziprasidone-Bicalutamide Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Ziprasidone				Bicalutamide
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Ziprasidone and Bicalutamide

Recommended Action
Management		Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.

References
1	Canadian Pharmacists Association.
2	Cerner Multum, Inc. "Australian Product Information.".
3	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4	Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82. [PMID: 11691681]
5	Product Information. Geodon (ziprasidone). Pfizer US Pharmaceuticals, New York, NY.
6	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".